See more : EuroSite Power Inc. (EUSP) Income Statement Analysis – Financial Results
Complete financial analysis of Beam Therapeutics Inc. (BEAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beam Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nordic Group Limited (MR7.SI) Income Statement Analysis – Financial Results
- Rogers Communications Inc. (RCIAF) Income Statement Analysis – Financial Results
- GAM Holding AG (GMHLF) Income Statement Analysis – Financial Results
- Sterling Group Holdings Limited (1825.HK) Income Statement Analysis – Financial Results
- Eucrates Biomedical Acquisition Corp. (EUCR) Income Statement Analysis – Financial Results
Beam Therapeutics Inc. (BEAM)
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 377.71M | 60.92M | 51.84M | 24.00K | 18.00K | 0.00 | 0.00 |
| Cost of Revenue | 437.38M | 22.58M | 16.44M | 103.18M | 5.41M | 650.00K | 11.00K |
| Gross Profit | -59.67M | 38.34M | 35.40M | -103.16M | -5.39M | -650.00K | -11.00K |
| Gross Profit Ratio | -15.80% | 62.94% | 68.29% | -429,812.50% | -29,938.89% | 0.00% | 0.00% |
| Research & Development | 437.38M | 311.59M | 387.09M | 103.18M | 54.62M | 33.87M | 5.86M |
| General & Administrative | 116.81M | 87.81M | 57.22M | 29.61M | 20.55M | 11.87M | 2.02M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.81M | 87.81M | 57.22M | 29.61M | 20.55M | 11.87M | 2.02M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -71.00K | -10.04M | 378.00K |
| Operating Expenses | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M | 45.74M | 7.88M |
| Cost & Expenses | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M | 45.74M | 7.88M |
| Interest Income | 0.00 | 15.30M | 9.00K | 1.57M | 2.49M | 292.00K | 0.00 |
| Interest Expense | 0.00 | 15.30M | 9.00K | 1.57M | 187.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 20.01M | 22.58M | 16.44M | 9.47M | 5.41M | 650.00K | 11.00K |
| EBITDA | -156.47M | -324.33M | -392.47M | -128.03M | -71.65M | -45.09M | -7.99M |
| EBITDA Ratio | -41.43% | -659.03% | -799.13% | -269,270.83% | -384,644.44% | 0.00% | 0.00% |
| Operating Income | -176.49M | -338.48M | -392.47M | -132.76M | -75.15M | -45.74M | -7.88M |
| Operating Income Ratio | -46.73% | -555.61% | -757.01% | -553,166.67% | -417,522.22% | 0.00% | 0.00% |
| Total Other Income/Expenses | 45.32M | 78.30M | 21.83M | -61.83M | -3.17M | -71.00M | -122.00K |
| Income Before Tax | -131.16M | -260.18M | -370.64M | -194.59M | -78.33M | -116.74M | -8.00M |
| Income Before Tax Ratio | -34.73% | -427.08% | -714.91% | -810,800.00% | -435,144.44% | 0.00% | 0.00% |
| Income Tax Expense | 1.37M | 3.41M | -29.28M | 61.83M | 116.00K | -71.00M | 500.00K |
| Net Income | -132.53M | -263.59M | -341.36M | -256.42M | -78.44M | -115.26M | -8.00M |
| Net Income Ratio | -35.09% | -432.68% | -658.44% | -1,068,433.33% | -435,788.89% | 0.00% | 0.00% |
| EPS | -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
| EPS Diluted | -1.72 | -3.76 | -5.31 | -5.49 | -1.53 | -3.28 | -0.62 |
| Weighted Avg Shares Out | 77.15M | 70.02M | 64.23M | 46.73M | 51.34M | 35.14M | 12.95M |
| Weighted Avg Shares Out (Dil) | 77.15M | 70.02M | 64.23M | 46.73M | 51.34M | 35.14M | 12.95M |
Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now
Inside Cathie Wood's Portfolio: 3 Stocks She Is Betting Millions On
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?
Beam Therapeutics up 10% on $600m Lilly deal
Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Source: https://incomestatements.info
Category: Stock Reports